Experienced in Multiple Sclerosis (MS)

Kai-chen H. Wang

TPQ, TW 
Experienced in Multiple Sclerosis (MS)
TPQ, TW 
OverviewLocationsClinical Research

Overview

Kai-chen Wang practices in Taiwan. Wang is rated as an Experienced expert by MediFind in the treatment of Multiple Sclerosis (MS). Their top areas of expertise are Transverse Myelitis, Neuromyelitis Optica, Optic Neuritis, Primary Lateral Sclerosis, and Colostomy.

Their clinical research consists of co-authoring 24 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles and participated in 1 clinical trial in the study of Multiple Sclerosis (MS).

Locations

TPQ, Taiwan
Other Locations
45 Zhenxing Street, Taiwan 112, Beitou, TPQ, Taiwan
Chang-hua, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3

24 Total Publications

An innovative AQP4 loop C-targeted monoclonal antibody reduces complement-dependent cytotoxicity and lessens experimental neuromyelitis optica.
An innovative AQP4 loop C-targeted monoclonal antibody reduces complement-dependent cytotoxicity and lessens experimental neuromyelitis optica.
Journal: Multiple sclerosis and related disorders
Published: July 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile